Magic mushroom compound enters final testing for depression
NCT ID NCT06308653
Summary
This study is testing whether a single dose of psilocybin, the active compound in 'magic mushrooms,' can help reduce symptoms of major depression. About 240 adults with depression will receive either a high dose, a low dose, or a placebo pill, all accompanied by therapy sessions before and after. Researchers will measure changes in depression symptoms over 43 days and follow participants for a full year, with the option for additional doses if symptoms return.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AIM Trials, LLC
Plano, Texas, 75093, United States
-
Bronx Veterans Research Foundation at the James J. Peters VAMC
The Bronx, New York, 10468, United States
-
Cedar Clinical Research
Draper, Utah, 84020, United States
-
Cedar Clinical Research, Inc.
Murray, Utah, 84107, United States
-
CenExel iResearch, LLC
Decatur, Georgia, 30030, United States
-
Clinical Neuroscience Solutions Inc.
Jacksonville, Florida, 32256, United States
-
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, 32801, United States
-
Clinical Trials of Texas, LLC
San Antonio, Texas, 78229, United States
-
Connecticut Mental Health Center, Yale University
New Haven, Connecticut, 06519, United States
-
Emory University
Atlanta, Georgia, 30329, United States
-
Global Medical Institutes, LLC; Princeton Medical Institute
Princeton, New Jersey, 08540, United States
-
Great Lakes Clinical Trials
Chicago, Illinois, 60640, United States
-
Innovative Clinical Research, Inc.
Lauderhill, Florida, 33319, United States
-
Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research
Baltimore, Maryland, 21224, United States
-
Kadima Neuropsychiatry Institute
La Jolla, California, 92037, United States
-
Mountain View Clinical Research
Denver, Colorado, 80209, United States
-
NYU Clinical & Translational Science Institute
New York, New York, 10016, United States
-
Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners
Santa Monica, California, 90404, United States
-
Preferred Research Partners, Inc.
Little Rock, Arkansas, 72211, United States
-
Preferred Research Partners-NWA, LLC
Fayetteville, Arkansas, 72703, United States
-
Psychedelic Science Institute
Santa Monica, California, 90404, United States
-
Seattle Neuropsychiatric Treatment Center
Bellevue, Washington, 98004, United States
-
Sunstone Medical PC
Rockville, Maryland, 20850, United States
-
University of Alabama Clinical Research Unit
Birmingham, Alabama, 35209, United States
-
University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) Center
Albuquerque, New Mexico, 87106, United States
-
VA Nebraska Western Iowa Health Care System
Omaha, Nebraska, 68105, United States
-
VA Portland Health Care System
Vancouver, Washington, 98661, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
West LA VA Medical Center - Mental Health Department
Los Angeles, California, 90073, United States
Conditions
Explore the condition pages connected to this study.